| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 11/29/2001 | WO2001089595A1 Polymer surface having biologically active properties and methods for the production thereof |
| 11/29/2001 | WO2001089593A1 Transfection system |
| 11/29/2001 | WO2001089589A1 A novel treatment for cough |
| 11/29/2001 | WO2001089575A1 Rapidly-disintegrating tablets for animals |
| 11/29/2001 | WO2001089574A1 Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof |
| 11/29/2001 | WO2001089573A1 Method of stabilizing preparation |
| 11/29/2001 | WO2001089572A1 Systems and methods for topical treatment with nitric oxide |
| 11/29/2001 | WO2001089563A1 Recombinant or purified polyclonal antibodies for treating allergy |
| 11/29/2001 | WO2001089561A1 Aids vaccines |
| 11/29/2001 | WO2001089558A2 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
| 11/29/2001 | WO2001089557A2 Methods for preventing strokes by inducing tolerance to e-selectin |
| 11/29/2001 | WO2001089554A2 Treatment of acute coronary syndrome with glp-1 |
| 11/29/2001 | WO2001089545A1 Antiviral methods and compositions |
| 11/29/2001 | WO2001089544A1 Antimigraine combination comprising sapindus and emblica extracts |
| 11/29/2001 | WO2001089542A2 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant |
| 11/29/2001 | WO2001089538A2 Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| 11/29/2001 | WO2001089536A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| 11/29/2001 | WO2001089523A1 New pharmaceutical composition and the process for its preparation |
| 11/29/2001 | WO2001089522A1 Compositions and methods for administration of pharmacologically active compounds |
| 11/29/2001 | WO2001089520A2 Dehydroascorbic acid formulations and uses thereof |
| 11/29/2001 | WO2001089514A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 11/29/2001 | WO2001089512A1 Drugs acting on the bronchi |
| 11/29/2001 | WO2001089511A2 Superficial therapeutic system containing o-acetylsalicylic acid, for treating skin pain |
| 11/29/2001 | WO2001089507A1 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE |
| 11/29/2001 | WO2001089506A1 Medicaments for treating colics |
| 11/29/2001 | WO2001089496A2 Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics |
| 11/29/2001 | WO2001089495A2 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
| 11/29/2001 | WO2001089494A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
| 11/29/2001 | WO2001089493A2 Compositions containing a benzamide disulfide derivative for treating allergic diseases |
| 11/29/2001 | WO2001089492A1 Novel composition |
| 11/29/2001 | WO2001089491A1 Novel process |
| 11/29/2001 | WO2001089490A1 Dosage of transdermal delivery systems |
| 11/29/2001 | WO2001089489A2 Transdermal application of active agents directly via the carotid artery |
| 11/29/2001 | WO2001089488A1 Plaster containing estrogen, with an active agent reservoir based on ethylcellulose, polyoxyethylene lauryl alcohol and an ethylene-vinylacetate-vinylpyrrolidone copolymer |
| 11/29/2001 | WO2001089487A1 Transdermal therapeutical system with a reduced tendency of the active substance to crystallize |
| 11/29/2001 | WO2001089486A1 Nonoral preparation having three-layer structure |
| 11/29/2001 | WO2001089485A1 Rapidly disintegrating tablet and process for the manufacture thereof |
| 11/29/2001 | WO2001089484A2 Method for increasing the compressibility of poorly binding powder materials |
| 11/29/2001 | WO2001089483A1 Tablets and methods for modified release of hydrophilic and other active agents |
| 11/29/2001 | WO2001089482A2 Method for preparing microparticles having a selected polymer molecular weight |
| 11/29/2001 | WO2001089481A1 Prolonged release microspheres for injection delivery and preparation method |
| 11/29/2001 | WO2001089480A1 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 11/29/2001 | WO2001089479A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 11/29/2001 | WO2001089478A1 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof |
| 11/29/2001 | WO2001089477A2 Controlled release of materials from polymer matrices |
| 11/29/2001 | WO2001089476A1 Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| 11/29/2001 | WO2001089475A1 Inhalation therapy decongestant with foraminous carrier |
| 11/29/2001 | WO2001089474A2 O/w emulsion |
| 11/29/2001 | WO2001089473A1 Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| 11/29/2001 | WO2001089455A2 System and method for assessing the performance of a pharmaceutical agent delivery system |
| 11/29/2001 | WO2001089446A1 Device for the coating of granulates and seeds |
| 11/29/2001 | WO2001089445A1 Blister package for topiramate tablets |
| 11/29/2001 | WO2001089431A1 Combination sis and vacuum bandage and method |
| 11/29/2001 | WO2001089319A2 Tryptophan source from plants and uses therefor |
| 11/29/2001 | WO2001046150A3 Quinolone compounds for use in treating viral infections |
| 11/29/2001 | WO2001041738A3 Lipid carrier compositions with protected surface reactive functions |
| 11/29/2001 | WO2001037816A3 Coating of tablet cores |
| 11/29/2001 | WO2001028544A3 Dialysis solution including polyglycol osmotic agent |
| 11/29/2001 | WO2001026706A3 Drug delivery catheters that attach to tissue and methods for their use |
| 11/29/2001 | WO2001021211A3 Process for lessening polymorphic conversion of a drug |
| 11/29/2001 | WO2000045792A8 Hydrogel particle formulations |
| 11/29/2001 | US20010047161 Osmotically-driven fluid dispenser and composition |
| 11/29/2001 | US20010047157 Delivery system for topical skin care agents |
| 11/29/2001 | US20010047082 Soluble keratin peptide |
| 11/29/2001 | US20010047074 Self-assembling colloidal carriers for protein delivery |
| 11/29/2001 | US20010047034 Inhibiting oxidative degradation of pharmaceutical formulations |
| 11/29/2001 | US20010047009 'anti-plaque emulsions and products containing same' |
| 11/29/2001 | US20010047004 Oxazolidinone thioamides with piperazine amide substituents |
| 11/29/2001 | US20010047000 E.g., ranolazine |
| 11/29/2001 | US20010046990 (-)3-(4-(2-(phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropionic acic or a salt for treating type 2 diabetes |
| 11/29/2001 | US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain |
| 11/29/2001 | US20010046984 Four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor |
| 11/29/2001 | US20010046982 Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension |
| 11/29/2001 | US20010046970 Inhibition of selectin binding |
| 11/29/2001 | US20010046969 Administering a disaccharide such as maltose or trehalose, optionally along with Vitamin C or a derivative, to increase saliva excretion; treating Sjogren's syndrome and xerostomia |
| 11/29/2001 | US20010046964 Drug core with two coated membrane barriers, one of which is composed of an enteric polymer and the other with a combination of an enteric polymer and a water soluble polymer |
| 11/29/2001 | US20010046961 Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel |
| 11/29/2001 | US20010046957 Administering interferon-alpha or a pegylated derivative and a salt or prodrug of mycophenolic acid |
| 11/29/2001 | US20010046705 Complex of nucleic acid and biodegradable cationic polyhydroxylated molecule (e.g., maltodextrin grafted with glycidyltrimethylammonium chloride); protects nucleic acid during transfection in to a cell |
| 11/29/2001 | US20010046697 Bacillus natto culture extract |
| 11/29/2001 | US20010046520 A topical virucidal frmulation comprising an inorganic halide, an oxidising agent capable of generating hypohalite ions in aqueous solution, a sulfamic acid, a non-reducing organic acid, an inorganic phosphate, and excipients |
| 11/29/2001 | US20010046519 Compositions for nasal administration |
| 11/29/2001 | US20010046518 Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
| 11/29/2001 | US20010046517 Irridiating a part of film coating layer containing one or more colorants with light to form solid preperation coated with a continuous film coating layer; the film coating agent consists of hydroxypropylmethyl cellulose or methyl cellulose |
| 11/29/2001 | US20010046516 Combining a sustained release excipient comprises a gelling agent, an ionizable gel strength enhancer and inert diluent with a medicament in amorphous form and a wetting agent and then drying and millilng the combined mixture |
| 11/29/2001 | US20010046515 Core formulation |
| 11/29/2001 | US20010046514 An antifungal medicine is incorporated into the nylon type fabric of sock or pair of socks which would be used to fight athelete's foot or any other type of foot aliment which would be treated with medicine |
| 11/29/2001 | US20010046511 Water soluble film for oral administration with instant wettability |
| 11/29/2001 | US20010046507 Cosmetic and pharmaceutical oil in water emulsion comprising polyether modified polysiloxanes |
| 11/29/2001 | US20010046505 An implantable medical device comprising a polyarylate, polymerized as a random block copolymer of a dicarboxylic acid with both tyrosine-derived diphenol and poly (alkylene oxide) in a specific ratio; used for drug delivery |
| 11/29/2001 | US20010046504 Film-coated tablet with cyclophosphamide as active compound, comprising in the core cyclophosphamide, one or more fillers, one or more dry binders but no preswollen starch, flow regulators and lubricants |
| 11/29/2001 | US20010046503 Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| 11/29/2001 | US20010046490 Cell surface molecule-induced macrophage activation |
| 11/29/2001 | US20010046481 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 11/29/2001 | US20010046478 Water soluble lacquers in combination with topical and systemic antimycotics |
| 11/29/2001 | US20010046476 Reactive group covalently bonded to a bactericide, flavorant and/or essential oil compound, hydrolyzable in aqueous solution for slow release |
| 11/29/2001 | US20010046475 Calcium and orthophosphate ions are soluble until their diffusion into the subsurface of the dental enamel; anticarie agents |
| 11/29/2001 | US20010046474 Stabilized preparations for use in metered dose inhalers |
| 11/29/2001 | US20010046473 Gastric-retained pharmaceutical composition and method for its use |
| 11/29/2001 | US20010046472 Inclusion of excipients that create a burst release following the initial rapid release, methylphenidate or Ritalin" |